Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-05-08 Share Issue/Capital Cha…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that a previously approved 'share capital increase' has now been 'registered with the Norwegian Register of Business Enterprises'. It details the change in the total number of shares and the new total share capital. This directly relates to a change in the company's capital structure through the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general financing update (CAP) because it is a specific registration of an already approved issuance, nor is it a transaction in own shares (POS) which typically refers to buybacks or treasury stock movements.
2023-05-08 English
Arctic Bioscience - Q1 2023 Operational update - HeROPA clinical trial approved in all 5 countries and ongoing
Regulatory Filings Classification · 100% confidence The document provides a detailed operational and financial update for the first quarter (Q1 2023). It includes key performance indicators (KPIs), revenue figures, EBITDA, cash position, updates on clinical trials (HeROPA), business segment performance (Nutra), and subsequent events related to an acquisition and capital increase. This structure—covering a specific fiscal period (Q1) with detailed financial metrics and operational narrative—is characteristic of a comprehensive quarterly report, which aligns with the definition of an Interim / Quarterly Report (IR). It is more detailed than a simple Earnings Release (ER) and is not a transcript (CT) or a general presentation (IP).
2023-05-08 English
Arctic Bioscience - 1.kv. 2023 oppdatering - HeROPA-studien godkjent i alle fem land og er pågående
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly update from Arctic Bioscience for Q1 2023. It contains specific financial data (revenue, EBITDA, capex, liquidity) and detailed management commentary on business operations, clinical trial progress (HeROPA), and market outlook. It is not a mere announcement of a report, but the report itself, providing substantive financial and operational analysis for a period shorter than a full fiscal year. Therefore, it is classified as an Interim/Quarterly Report. Q1 2023
2023-05-08 Norwegian
Arctic Bioscience - Meldepliktig handel
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a 'Share Purchase' transaction by a 'Member of the board' (Tore Andreas Frøysa Tønseth) involving 'Common shares in ABS'. This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by executives and directors.
2023-04-24 English
Arctic Bioscience - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a 'Share Purchase' transaction by a 'Member of the board' (Tore Andreas Frøysa Tønseth) involving 'Common shares in ABS'. This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by executives and directors.
2023-04-24 English
Arctic Bioscience - Meldepliktig handel
Share Issue/Capital Change Classification · 99% confidence The document text is a short announcement in Norwegian ('Meldepliktig handel') detailing a transaction made by a related party (Ronja Capital II AS) of a director (Tore A. Tønseth) in the company's shares following a capital increase. This clearly falls under the definition of insider trading or director's dealing, as it reports personal share transactions by company executives/related parties, referencing MAR Article 19. The specific filing type corresponding to this is 'Director's Dealing' (DIRS). Although it mentions an attached notification ('Jf. vedlagt melding om handel'), the core content is the disclosure itself, making DIRS more specific than the general RPA or RNS fallback.
2023-04-24 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.